|This strain is now distributed by the Mutant Mouse Regional Resource Center. Please refer to the Mutant Mouse Regional Resource Center (MMRRC) for ordering information and strain details on B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax
MMRRC Stock Number 034835. |
As a designated MMRRC center, The Jackson Laboratory will continue to distribute these mice at the same high health and
quality standards but ordering is exclusively provided through the MMRRC.
|These transgenic mice (formerly JAX Stock No. 006005) express a chimeric mouse/human amyloid precursor protein (APPswe) under the control of the mouse prion protein promoter. This mutant mouse strain may be useful in studies of Alzheimer's Disease.|
Former Names B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/J (Changed: 11-AUG-11 ) B6.Cg-Tg(APPswe)E1-2Dbo/J (Changed: 13-FEB-07 ) Type Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Generation N15p
Donating Investigator Dr. David R Borchelt, University of Florida
These transgenic mice express a chimeric mouse/human amyloid precursor protein (APPswe) under the control of the mouse prion protein promoter. Mice that are hemizygous for the transgene are viable and fertile. More than half of the female hemizygous mice do not survive past 15 months of age. This mutant mouse strain may be useful in studies of Alzheimer's Disease.
A transgenic construct a chimeric mouse/human amyloid precursor protein (APPswe) under the control of the mouse prion protein promoter was injected into fertilized C57BL/6J X C3HeJ F2 mouse eggs. Founder line E1-2 was established. The mice were then backcrossed to C57BL/6J for more than 14 generations.
Alzheimer's Disease Models
005987 129-Achetm1Loc/J 006409 129S1.129(Cg)-Tg(APPSw)40Btla/Mmjax 008077 129S1/Sv-Bchetm1Loc/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 014556 129S6/SvEv-Apoetm4Mae/J 006555 A.129(B6)-Tg(APPSw)40Btla/Mmjax 005708 B6.129-Apbb1tm1Quhu/J 004714 B6.129-Bace1tm1Pcw/J 004098 B6.129-Klc1tm1Gsn/J 004193 B6.129-Psen1tm1Mpm/J 003615 B6.129-Psen1tm1Shn/J 005300 B6.129-Tg(APPSw)40Btla/Mmjax 005617 B6.129P-Psen2tm1Bdes/J 002609 B6.129P2-Nos2tm1Lau/J 007685 B6.129P2-Psen1tm1Vln/J 007999 B6.129P2-Sorl1Gt(Ex255)Byg/J 008087 B6.129S1-Bchetm1Loc/J 002509 B6.129S2-Plautm1Mlg/J 005301 B6.129S2-Tg(APP)8.9Btla/J 004163 B6.129S4-Cdk5r1tm1Lht/J 010959 B6.129S4-Grk5tm1Rjl/J 010960 B6.129S4-Grk5tm2Rjl/J 002213 B6.129S4-Ngfrtm1Jae/J 006406 B6.129S4-Tg(APPSwLon)96Btla/Mmjax 006469 B6.129S4-Tg(PSEN1H163R)G9Btla/J 012564 B6.129S5-Dhcr24tm1Lex/SbpaJ 004142 B6.129S7-Aplp2tm1Dbo/J 004133 B6.129S7-Apptm1Dbo/J 007251 B6.129X1-Mapttm1Hnd/J 013040 B6.Cg-Apoetm1Unc Ins2Akita/J 005642 B6.Cg-Clutm1Jakh/J 005491 B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 009126 B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/Mmjax 005866 B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax 008730 B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax 005864 B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax 007575 B6.Cg-Tg(CAG-Ngb,-EGFP)1Dgrn/J 016197 B6.Cg-Tg(CAG-OTC/CAT)4033Prab/J 005855 B6.Cg-Tg(Camk2a-Prkaca)426Tabe/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 004996 B6.Cg-Tg(DBH-Gal)1923Stei/J 007673 B6.Cg-Tg(Gad1-EGFP)3Gfng/J 004662 B6.Cg-Tg(PDGFB-APP)5Lms/J 006293 B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2Mmjax 006006 B6.Cg-Tg(Prnp-APP)A-2Dbo/J 008596 B6.Cg-Tg(Prnp-Abca1)EHol/J 007180 B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J 007182 B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J 005999 B6.Cg-Tg(SBE/TK-luc)7Twc/J 012597 B6.Cg-Tg(Thy1-COL25A1)861Yfu/J 007051 B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax 007052 B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax 007049 B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax 009337 B6.FVB-Tg(Prnp-RTN3)2Yanr/J 006394 B6;129-Apba2tm1Sud Apba3tm1Sud Apba1tm1Sud/J 008364 B6;129-Chattm1(cre/ERT)Nat/J 008476 B6;129-Ncstntm1Sud/J 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 007605 B6;129P-Psen1tm1Vln/J 005618 B6;129P2-Bace2tm1Bdes/J 008333 B6;129P2-Dldtm1Ptl/J 002596 B6;129P2-Nos2tm1Lau/J 003822 B6;129S-Psen1tm1Shn/J 012639 B6;129S4-Mapttm3(HDAC2)Jae/J 012869 B6;129S6-Apbb2tm1Her/J 006410 B6;129S6-Chattm2(cre)Lowl/J 005993 B6;129S6-Pcsk9tm1Jdh/J 008636 B6;C-Tg(Prnp-APP695*/EYFP)49Gsn/J 007002 B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax 008169 B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J 000231 B6;C3Fe a/a-Csf1op/J 008850 B6;SJL-Tg(Mt1-LDLR)93-4Reh/AgnJ 003378 B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J 004462 B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 016556 B6N.129-Ptpn5tm1Pjlo/J 018957 B6N.129S6(B6)-Chattm2(cre)Lowl/J 024841 B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J 006554 B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax 012621 C.129S(B6)-Chrna3tm1.1Hwrt/J 002328 C.129S2-Plautm1Mlg/J 003375 C3B6-Tg(APP695)3Dbo/Mmjax 005087 C57BL/6-Tg(Camk2a-IDE)1Selk/J 005086 C57BL/6-Tg(Camk2a-MME)3Selk/J 008833 C57BL/6-Tg(Camk2a-UBB)3413-1Fwvl/J 007027 C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax 010800 C57BL/6-Tg(Thy1-PTGS2)300Kand/J 010703 C57BL/6-Tg(Thy1-PTGS2)303Kand/J 005706 C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J 006618 C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J 007677 CB6-Tg(Gad1-EGFP)G42Zjh/J 007072 CByJ.129P2(B6)-Nos2tm1Lau/J 006472 D2.129(B6)-Tg(APPSw)40Btla/Mmjax 007067 D2.129P2(B6)-Apoetm1Unc/J 013719 D2.Cg-Apoetm1Unc Ins2Akita/J 003718 FVB-Tg(GadGFP)45704Swn/J 013732 FVB-Tg(NPEPPS)1Skar/J 013156 FVB-Tg(tetO-CDK5R1*)1Vln/J 015815 FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ 002329 FVB.129S2-Plautm1Mlg/J 025105 FVB.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003753 FVB/N-Tg(Eno2CDK5R1)1Jdm/J 006143 FVB/N-Tg(Thy1-cre)1Vln/J 025104 FVB/N-Tg(tetO/Prnp-MAPT*P301L,-luc)Y74Dbo/J 008051 NOD.129P2(B6)-Ctsbtm1Jde/RclJ 008390 STOCK Apptm1Sud/J 012640 STOCK Hdac2tm1.2Rdp/J 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 004779 STOCK Mapttm1(EGFP)Klt/J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 014544 STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/JView Alzheimer's Disease Models (111 strains)Strains carrying other alleles of APP
006409 129S1.129(Cg)-Tg(APPSw)40Btla/Mmjax 006555 A.129(B6)-Tg(APPSw)40Btla/Mmjax 005300 B6.129-Tg(APPSw)40Btla/Mmjax 005301 B6.129S2-Tg(APP)8.9Btla/J 006406 B6.129S4-Tg(APPSwLon)96Btla/Mmjax 009126 B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/Mmjax 005864 B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax 004662 B6.Cg-Tg(PDGFB-APP)5Lms/J 006293 B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2Mmjax 006006 B6.Cg-Tg(Prnp-APP)A-2Dbo/J 007049 B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 004462 B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax 006004 B6C3-Tg(tetO-APPSwInd)885Dbo/Mmjax 007027 C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax 006472 D2.129(B6)-Tg(APPSw)40Btla/MmjaxView Strains carrying other alleles of APP (16 strains)Strains carrying other alleles of Prnp
012938 129-Prnptm2Edin/J 016925 129;B6-Del(10Grin3b-Tmem259)1Zang Tg(Prnp-C19ORF6,-GFP)6Zhang/J 003960 129S6-Tg(Prnp-GFP/cre)1Blw/J 005866 B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax 006006 B6.Cg-Tg(Prnp-APP)A-2Dbo/J 008596 B6.Cg-Tg(Prnp-Abca1)EHol/J 007180 B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J 007182 B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J 006823 B6.Cg-Tg(Prnp-SNCA*A53T)23Mkle/J 010700 B6.Cg-Tg(Prnp-TARDBP*A315T)95Balo/J 009337 B6.FVB-Tg(Prnp-RTN3)2Yanr/J 007002 B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax 008169 B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J 004479 B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J 018917 B6;SJL-Tg(Prnp-CCS)17Jlel/J 003378 B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J 008216 B6CBA(FVB)-Tg(Prnp-TBP*)71-16Xjl/J 008075 B6CBA-Tg(Prnp-TBP*)105Xjl/J 008083 B6CBA-Tg(Prnp-TBP*)13Xjl/J 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 024841 B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J 017907 B6N.Cg-Tg(Prnp-TARDBP)96Dwc/J 017933 B6N.Cg-Tg(Prnp-TARDBP*Q331K)103Dwc/J 017930 B6N.Cg-Tg(Prnp-TARDBP*Q331K)109Dwc/J 025402 B6SJL-Tg(Prnp-Immt/SOD1)1Gmnf/J 025403 B6SJL-Tg(Prnp-Immt/SOD1*G93A)7Gmnf/J 016201 B6SJL-Tg(Prnp-TARDBP)4Jlel/J 016203 B6SJL-Tg(Prnp-TARDBP*A315T)23Jlel/J 016608 C57BL/6-Tg(Prnp-TARDBP)3cPtrc/J 017604 C57BL/6-Tg(Prnp-TARDBP*M337V)4Ptrc/J 018122 FVB.129S7(B6)-Prnptm1Cwe/J 025104 FVB/N-Tg(tetO/Prnp-MAPT*P301L,-luc)Y74Dbo/J 017678 FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J 017744 FVB;129-Tg(Prnp-SNCA*A53T)AAub/J 017916 STOCK Tg(Prnp-FUS)WT3Cshw/J 016144 STOCK Tg(Prnp-TARDBP)4Jlel/J 016143 STOCK Tg(Prnp-TARDBP*A315T)23Jlel/J 008212 STOCK Tg(SMN2)89Ahmb Smn1tm1Msd Tg(Prnp-SMN)92Ahmb/JView Strains carrying other alleles of Prnp (38 strains)
View Related Disease (OMIM) TermsRelated Disease (OMIM) Terms provided by MGI
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
- Potential model based on transgenic expression of a human gene that is associated with this disease. Phenotypic similarity to the human disease has not been tested.View Mammalian Phenotype TermsMammalian Phenotype Terms provided by MGIassigned by genotype
- nervous system phenotype
- amyloid beta deposits
- 14-15 month old mutants backcrossed 5- or 10 generations tend to have higher accumulation of amyloid compared to Tg(APP695)3Dbo at that age (MGI Ref ID J:109847)
- behavior/neurological phenotype
- abnormal locomotor behavior
- in radial maze testing, male mutants backcrossed 5-7 generations show high motor reactivity compared to females or control animals, and entered the closest arm of the maze which prevented them from learning the task (MGI Ref ID J:109847)
- decreased vertical activity
- at 12-13 months, mice backcrossed 5-7 generations show fewer rearing reactions compared to nontransgenic littermates (MGI Ref ID J:109847)
- at 12-13 months, males backcrossed 5-7 generations are less active than controls in inner cells of open field (MGI Ref ID J:109847)
- abnormal object recognition memory
- as females age (13-14 months of age), significant difference compared to female controls is observed in trials with longest (<60 minute) delays (MGI Ref ID J:109847)
- abnormal spatial learning
- 12-13 month old males and females backcrossed 5-7 generations show poorer performance in probe trials in the Morris water maze; females spent less time in correct quadrant until fourth consectutive session (MGI Ref ID J:109847)
- upon repeat testing of the same females one month later, difference between mutants and controls is more robust; repeated testing had no effect on performance (MGI Ref ID J:109847)
- increased anxiety-related response
- at 12-13 months, females backcrossed 5-7 generations are less active in visiting open arms in plus maze; combined with reduced rearing reactions, females may have higher anxiety levels (MGI Ref ID J:109847)
- homeostasis/metabolism phenotype
- amyloid beta deposits
- 14-15 month old mutants backcrossed 5- or 10 generations tend to have higher accumulation of amyloid compared to Tg(APP695)3Dbo at that age (MGI Ref ID J:109847)View Research Applications
|Allele Name||transgene insertion E1-2, David R Borchelt|
|Allele Type||Transgenic (Humanized sequence, Inserted expressed sequence)|
|Common Name(s)||E1-2 line; Mo/Hu APPswe; Mo/Hu APPswe line E1-2; line E1-2;|
|Strain of Origin||(C57BL/6J x C3H/HeJ)F2|
|Expressed Gene||APP, amyloid beta (A4) precursor protein, human|
|Promoter||Prnp, prion protein, mouse, laboratory|
|General Note||Three transgenic lines were generated and designated by the authors lines Q2-2, E1-2 and C3-3 (Tg(APP695)3Dbo). They were estimated, on the basis of Southern blot analysis, to carry 3-10 copies of the transgene.|
|Molecular Note||This transgene expresses a modified mouse amyloid precursor protein cDNA encoding the 695-amino acid isoform with a "humanized" Abeta domain amino acid sequence that includes the familial Alzheimer disease- (FAD-) associated Swedish double mutation (Lys595Asn and Met596Leu). The cDNA was inserted into an expression cassette containing the promoter, 5' intronic and 3' untranslated region sequences of the mouse prion protein gene. [MGI Ref ID J:80782]|
Savonenko AV; Xu GM; Price DL; Borchelt DR; Markowska AL. 2003. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. Neurobiol Dis 12(3):194-211. [PubMed: 12742740] [MGI Ref ID J:109847]
Borchelt DR; Davis J; Fischer M; Lee MK; Slunt HH; Ratovitsky T; Regard J; Copeland NG; Jenkins NA; Sisodia SS; Price DL. 1996. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal 13(6):159-63. [PubMed: 9117892] [MGI Ref ID J:80782]
Hou Y; Aboukhatwa MA; Lei DL; Manaye K; Khan I; Luo Y. 2010. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology 58(6):911-20. [PubMed: 19917299] [MGI Ref ID J:179562]
Animal Health ReportsProduction of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.
Breeding & Husbandry When maintaining a live colony, these mice are bred as hemizygotes.
For Licensing and Use Restrictions view the link(s) below:
- Strain(s) not available to companies or for-profit entities.
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.